JPMorgan Chase & Co. started coverage on shares of CeriBell (NASDAQ:CBLL – Free Report) in a research note released on Tuesday, MarketBeat Ratings reports. The firm issued an overweight rating and a $32.00 price target on the stock.
CBLL has been the topic of several other research reports. TD Cowen began coverage on CeriBell in a research report on Tuesday. They set a “buy” rating and a $31.00 target price on the stock. William Blair initiated coverage on CeriBell in a research note on Tuesday. They set an “outperform” rating on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus price target of $31.00.
Read Our Latest Stock Analysis on CBLL
CeriBell Stock Down 2.3 %
CeriBell Company Profile
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Read More
- Five stocks we like better than CeriBell
- Comparing and Trading High PE Ratio Stocks
- Dot Ai IPO: CEO Ed Nabrotzky Shares Vision for Logistics Future
- Options Trading – Understanding Strike Price
- The Hottest Markets to Watch After the Fed’s 25 Bps Rate Cut
- Compound Interest and Why It Matters When Investing
- The Top 5 Performing S&P 500 Stocks YTD in 2024
Receive News & Ratings for CeriBell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CeriBell and related companies with MarketBeat.com's FREE daily email newsletter.
